-
1
-
-
0034712536
-
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
-
Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
-
(2000)
Lancet
, vol.355
, pp. 1041-1047
-
-
Douillard, J.Y.1
Cunningham, D.2
Roth, A.D.3
-
2
-
-
1842569206
-
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
-
Goldberg RM, Sargent DJ, Morton RF, at al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
-
(2004)
J Clin Oncol
, vol.22
, pp. 23-30
-
-
Goldberg, R.M.1
Sargent, D.J.2
Morton, R.F.3
at al4
-
3
-
-
2542615200
-
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
-
Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
-
(2004)
N Engl J Med
, vol.350
, pp. 2343-2351
-
-
Andre, T.1
Boni, C.2
Mounedji-Boudiaf, L.3
-
4
-
-
1342290189
-
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
-
Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
-
(2004)
J Clin Oncol
, vol.22
, pp. 229-237
-
-
Tournigand, C.1
Andre, T.2
Achille, E.3
-
5
-
-
24644457747
-
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale
-
Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-4875.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4866-4875
-
-
Colucci, G.1
Gebbia, V.2
Paoletti, G.3
-
6
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
7
-
-
34249293549
-
Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC)
-
Presented at the, January 19-21, Orlando, Fla. Abstract 238
-
Saltz LB, Clarke S, Diaz-Rubio E, et at. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of metastatic colorectal cancer (MCRC). Presented at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, 2007; January 19-21, 2007; Orlando, Fla. Abstract 238.
-
(2007)
American Society of Clinical Oncology Gastrointestinal Cancer Symposium
-
-
Saltz, L.B.1
Clarke, S.2
Diaz-Rubio, E.3
et at4
-
8
-
-
34249794358
-
-
Eloxatin [package insert, Bridgewater, NJ: Sanofi-Aventis; 2006
-
Eloxatin [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2006.
-
-
-
-
9
-
-
34249819142
-
-
Camptosar [package insert, New York, NY: Pfizer Inc/Pharmacia & Upjohn Co
-
Camptosar [package insert]. New York, NY: Pfizer Inc/Pharmacia & Upjohn Co.
-
-
-
-
10
-
-
78649965752
-
-
National Cancer Institute, Available at:, Accessed May 4
-
National Cancer Institute. Colon Cancer (PDQ): Treatment. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/colon/ HealthProfessional/ page9. Accessed May 4, 2007.
-
(2007)
Colon Cancer (PDQ): Treatment
-
-
-
11
-
-
2142703727
-
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
-
Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1209-1214
-
-
Grothey, A.1
Sargent, D.2
Goldberg, R.M.3
Schmoll, H.J.4
-
12
-
-
33644825856
-
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line
-
Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23:9441-9442.
-
(2005)
J Clin Oncol
, vol.23
, pp. 9441-9442
-
-
Grothey, A.1
Sargent, D.2
-
13
-
-
0345403552
-
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
-
Kohne CH, Schoffski P, Wilke H, et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998;16:418-426.
-
(1998)
J Clin Oncol
, vol.16
, pp. 418-426
-
-
Kohne, C.H.1
Schoffski, P.2
Wilke, H.3
-
14
-
-
2642642086
-
Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? a phase II study
-
Hartmann JT, Kohne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C. Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? a phase II study. Oncology 1998;55:320-325.
-
(1998)
Oncology
, vol.55
, pp. 320-325
-
-
Hartmann, J.T.1
Kohne, C.H.2
Schmoll, H.J.3
Daikeler, T.4
Kanz, L.5
Bokemeyer, C.6
-
15
-
-
17644382288
-
Critical evaluation of current treatments in metastatic colorectal cancer
-
Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 2005;10:250-261.
-
(2005)
Oncologist
, vol.10
, pp. 250-261
-
-
Venook, A.1
-
16
-
-
33749852995
-
Therapy for metastatic colorectal cancer
-
Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist 2006;11:981-987.
-
(2006)
Oncologist
, vol.11
, pp. 981-987
-
-
Goldberg, R.M.1
|